Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: Long-term follow-up of a pilot study from the Wisconsin Oncology Network

Vaishalee P. Kenkre, Walter L. Long, Jens C. Eickhoff, Jules H. Blank, Thomas A. McFarland, Wayne Bottner, Hamied Rezazedeh, Jae E. Werndli, Howard H. Bailey, Brad S. Kahl

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 35 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with maintenance rituximab. The complete response rate was 64%, and median progression-free survival (PFS) 37 months. Herein, we update our results, now with a median follow-up of 62 months. The median PFS is unchanged and the median overall survival (OS) is 70 months. The proportion of patients surviving at 5 years is 62%, comparable to studies using intensive strategies in similar patient populations. No late toxicities were noted in our cohort. These long-term results suggest that the modified R-hyperCVAD regimen with maintenance rituximab is an excellent option for older patients with newly diagnosed mantle cell lymphoma.

Original languageEnglish
Pages (from-to)1675-1680
Number of pages6
JournalLeukemia and Lymphoma
Volume52
Issue number9
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Keywords

  • Mantle cell lymphoma
  • modified R-hyperCVAD
  • non-Hodgkin's lymphoma
  • rituximab maintenance

Fingerprint Dive into the research topics of 'Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: Long-term follow-up of a pilot study from the Wisconsin Oncology Network'. Together they form a unique fingerprint.

  • Cite this

    Kenkre, V. P., Long, W. L., Eickhoff, J. C., Blank, J. H., McFarland, T. A., Bottner, W., Rezazedeh, H., Werndli, J. E., Bailey, H. H., & Kahl, B. S. (2011). Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: Long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leukemia and Lymphoma, 52(9), 1675-1680. https://doi.org/10.3109/10428194.2011.580404